First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

Phase 2 Active not recruiting 55 enrolled Qilu Hospital of Shandong University

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Disitamab Vedotin in Combination With Tirelizumab and S-1 as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Timeline

Start: 2023-02-10
Primary completion: 2024-12-29
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Disitamab Vedotin	Monoclonal antibody	2.5 mg/kg	Intravenous
Subject	S-1	Small molecule	40 mg	Oral
Subject	S-1	Small molecule	60 mg	Oral
Subject	Tislelizumab	Monoclonal antibody	200 mg	Intravenous

Indications

No indication recorded.